Abstract:We report the synthesis and evaluation of a series of cell-permeable and N- versus O-selective sialyltransferase inhibitors. Inhibitor design entailed the functionalization of lithocholic acid at C(3) and at the cyclopentane ring side chain. Among the series, FCW34 and FCW66 were shown to inhibit MDA-MB-231 cell migration as effectively as ST3GALIII-gene knockdown did. FCW34 was shown to inhibit tumor growth, reduce angiogenesis, and delay cancer cell metastasis in animal models. Furthermore, FCW34 inhibited vessel development and suppressed angiogenic activity in transgenic zebrafish models. Our results provide clear evidence that FCW34-induced sialyltransferase inhibition reduces cancer cell metastasis by decreasing N-glycan sialylation, thus altering the regulation of talin/integrin/FAK/paxillin and integrin/NFκB signaling pathways.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01477?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01477</a>.Effect of 2aA–2eA on migration in MDA-MB-231 cells; effect of FCW34 on migration in MDA-MB-231 cells; effect of FCW66 on migration in MDA-MB-231 cells; effects of ST3GALIII siRNA knockdown efficiency in MDA-MB-231 cells; inhibition of integrin sialylation by sialyltransferase inhibitors in MDA-MB-231 cells; effects of sialyltransferase inhibitor FCW34 on tumor metastasis in MDA-MB-231 breast cancer cells in vivo; effects of sialyltransferase inhibitor FCW34 on toxicity assessment in MDA-MB-231 breast cancer cells in vivo; effects of sialyltransferase inhibitors on the integrin–FAK–paxillin pathway in MDA-MB-231 cells; effects of sialyltransferase inhibitors on the NFκB pathway in MDA-MB-231 cells; apparent permeability (Papp) values obtained for the reference compounds, FCW34, and FCW66 using the PAMPA model; endogenous expression of ST6GALI, ST3GALIII, ST3GALI, and ST6GALNACI proteins; comparison of binding modes of 2aA–2eA, 3cB–3dB, 4cC–4dC, AL10, LCAG, and Lith-O-ASP in the binding sites of two asymmetric polypeptide chains (A/B) of ST6GALI (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6QVT">6QVT</a>); computed physicochemical properties of the selected compounds used in this study; computational binding values of complex structure of ST6GALI-inhibitor; sensitization of tumors to ST inhibitors by regulation of the talin/integrin/FAK/paxillin and integrin/NFκB-signaling pathways; and experimental procedures, details of HPLC-determined purity data, HRMS results, and 1H and 13C NMR spectra of all final compounds and intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01477/suppl_file/jm0c01477_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01477/suppl_file/jm0c01477_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

S-Benproperine, an Active Stereoisomer of Benproperine, Suppresses Cancer Migration and Tumor Metastasis by Targeting ARPC2

Bexarotene: a Promising Anticancer Agent

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Peniciketal A, A Novel Spiroketal Compound, Exerts Anticancer Effects by Inhibiting Cell Proliferation, Migration and Invasion of A549 Lung Cancer Cells.

Identification of 1,4-Benzodiazepine-2,5-dione Derivatives As Potential Protein Synthesis Inhibitors with Highly Potent Anticancer Activity.

Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine As a WSB1 Degrader to Inhibit Cancer Cell Metastasis

Identification of Scutebarbatine B metabolites in rats using UHPLC-Q-Orbitrap-MS/MS and exploration of its mechanism of reversal multidrug resistance in breast cancer by network pharmacology and molecular docking studies

Design, synthesis, biological evaluation, in silico ADME prediction and molecular docking of pyrazole-benzamides as multitargeting protien kinase inhibitors

Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment

ARPC2 Targeting Inhibition Progress the Proliferation Suppression of Acute Myeloid Leukemia through PI3K-AKT Pathway

BHMPS Inhibits Breast Cancer Migration and Invasion by Disrupting Rab27a-Mediated EGFR and Fibronectin Secretion

Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects

Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay

Synthesis, crystal structure, DFT, Hirshfeld surface analysis, energy framework, docking and molecular dynamic simulations of (E)-4-(4-methylbenzyl)-6-styrylpyridazin-3(2H)-one as anticancer agent

Benzo-[a]-pyrene induces FAK activation and cell migration in MDA-MB-231 breast cancer cells

1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells

13-Butoxyberberine Bromide Inhibits Migration and Invasion in Skin Cancer A431 Cells

Novel ginsenoside derivative 20(S)-Rh2E2 suppresses tumor growth and metastasis in vivo and in vitro via intervention of cancer cell energy metabolism

Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis

Selective Targeting of the Androgen Receptor-Dna Binding Domain by the Novel Antiandrogen SBF-1 and Inhibition of the Growth of Prostate Cancer Cells

Synthesis, Anti-Cancer Evaluation of Benzenesulfonamide Derivatives As Potent Tubulin-Targeting Agents.